Home › Funds › Envision Financial Transparency, LLC › PBE
Envision Financial Transparency, LLC position in PBE
INVESCO BIOTECHNOLOGY & GENOME ETF
Envision Financial Transparency, LLC reported holding 4,488 shares of PBE (INVESCO BIOTECHNOLOGY & GENOME ETF) in its Q2 2026 13F filing — a position valued at US$371K, representing 0.37% of its reported portfolio and ranking #36 among its reported holdings. Envision Financial Transparency, LLC first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Envision Financial Transparency, LLC's PBE position evolved
Envision Financial Transparency, LLC first disclosed a stake in PBE in Q2 2026 at 4,488 shares (US$371K).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 4.49K | $371.25K | New |
About PBE and 13F data
PBE (INVESCO BIOTECHNOLOGY & GENOME ETF) is a company whose sector is not yet classified in our data. 28 other funds we track also report a position in PBE. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
More on Envision Financial Transparency, LLC
FAQ
How long has Envision Financial Transparency, LLC held PBE?
Envision Financial Transparency, LLC has disclosed PBE holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Envision Financial Transparency, LLC's current position in PBE?
As of Q2 2026, Envision Financial Transparency, LLC holds 4.49K shares of PBE (INVESCO BIOTECHNOLOGY & GENOME ETF), valued at $371.25K, representing 0.37% of its reported portfolio and ranking #36.
Has Envision Financial Transparency, LLC been buying or selling PBE?
In the latest 13F filing (Q2 2026), Envision Financial Transparency, LLC newly opened its position in PBE.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.